We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Vectura successfully concludes two paediatric studies to support the potential use of VR647, its wholly-owned drug/device combination asset for asthma patients.